Table 6.
Age’s distribution and osteoporosis among CFTR mutation groups
| Pancreatic status | Groups | N | Mean (months) | Standard deviation |
Confidential interval |
Minimum (months) | Maximum (months) | p-value | Osteoporosis (N/%) | p-value | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5% | 95% | ||||||||||
| |
No mutation identified |
44 |
211.75 |
217.501 |
145.62 |
277.88 |
25 |
932 |
|
8 (19%) |
|
| Pancreatic insufficiency + Pancreatic sufficiency |
One CFTR mutation identified |
51 |
201.18 |
165.050 |
154.76 |
247.60 |
11 |
782 |
0.854 |
9 (17.6%) |
|
| |
Two mutation identified |
84 |
220.06 |
188.643 |
179.12 |
261.00 |
7 |
1274 |
|
12 (14.3%) |
0.761 |
| Pancreatic insufficiency | One CFTR mutation identified |
35 |
221.57 |
216.17 |
147.31 |
295.83 |
25 |
932 |
|
7 (21.2%) |
|
| Two mutation identified | 43 | 198.81 | 171.31 | 146.09 | 251.54 | 11 | 782 | 0.940 | 5 (11.6%) | 0.345 | |
CFTR, Cystic fibrosis transmembrane regulator; N, number of patients.